PSS15 – Economic Evaluation for The Treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI) From The NHS Perspective: A Spending Predictor Model for Italy, Romania and Spain
Objectives Dalbavancin is a new innovative long-acting antimicrobial treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI) that allows clinicians to endorse an early discharge (ED) approach. Aim of this study was to develop a spending predictor model for evaluating the direct costs associated with the management of ABSSSI from a National Payer perspective…